A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors

摘要: Combination therapy via nanoparticulate systems has already been proposed as a synergistic approach for cancer treatment. Herein, undecylenic acid modified thermally hydrocarbonized porous silicon nanoparticles (UnTHCPSi NPs) loaded with sorafenib and surface-biofunctionalized anti-CD326 antibody (Ab) were developed chemo-immunotherapy in MCF-7 MDA-MB-231 breast cells. The cytocompatibility study showed no significant toxicity the bare antibody-conjugated UnTHCPSi (Un-Ab) NPs at concentrations lower than 200 μg·mL−1. Compared to UnTHCPSi, Un-Ab reduced premature drug release plasma, increasing probability of proper targeting. In addition, high cellular interaction subsequent internalization into cells expressing CD326 antigen demonstrated possibility improving antigen-mediated endocytosis While an vitro antitumor revealed higher inhibitory effect sorafenib-loaded compared drug-loaded positive cells, there was difference anti-proliferation impact both abovementioned negative suggesting appropriate receptor Ab-mediated delivery. It also shown that Ab can act immunotherapeutic agent by inducing dependent cytotoxicity enhancing effector immune phagocytosis cytokine secretion. Hence, nanovectors be applied simultaneous tumor-selective targeting immunotherapy.